MedTrace Logo

ATRIAL FIBRILATION OPPORTUNISTIC SCREENING AND STROKE (AFOSS).

NCT03589170 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 51410

Last updated 2018-07-17

No results posted yet for this study

Summary

People: The absolute prevalence of undiagnosed atrial fibrillation in individuals over 60 years of age is 2.2%, equivalent to 20.1% of the overall prevalence of AF and there is not sufficient evidence regarding the procedures that may be most effective for achieving an early diagnosis of AF and reducing the associated stroke risks.

Intervention: Characterize the ideal population for searching unknown atrial fibrillation and develop an understanding of actions that could be taken today to improve the diagnosis and management of AF.

C: Compare two large populations with and without opportunistic screening of AF about stroke incidence.

Outcome: MAIN OBJECTIVES

1. Compare two large populations with and without opportunistic screening of AF.
2. Relate the incidence of stroke episode with the AF diagnosis
3. Characterize the ideal population for searching unknown atrial fibrillation by making a multivariate predictor model.
4. Develop an understanding of actions that could be taken today to improve the diagnosis and management of AF.
5. Evaluate whether intervention results in improved outcomes

Conditions

Interventions

DIAGNOSTIC_TEST

Opportunistic atrial fibrillation screening

Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.

Sponsors & Collaborators

  • Jordi Gol Primary Health Research Institute

    collaborator UNKNOWN

  • University Rovira i Virgili

    collaborator OTHER

  • Catalan Institute of Health

    collaborator OTHER_GOV

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

    lead OTHER

Principal Investigators

  • Jose Maria Alegret-Colomè, PhD · University Rovira i Virgili

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-12-31
Completion
2019-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03589170 on ClinicalTrials.gov